NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

Summary

This is a single-arm, open-label, multi-center, Phase 1 study to determine safety and tolerability of an experimental therapy called NKX101 (allogeneic CAR NK cells targeting NKG2D ligands) in patients with relapsed/refractory AML or intermediate, high and very high risk relapsed/refractory MDS.

Timeline

Start

2020-09-21

Primary completion

2024-10-02

Completion

2039-07

Drugs

Indications